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Purpose: Selumetinib (AZD6244, ARRY-142886),
an oral mitogen activated kinase 1/2 inhibitor, is in
clinical development for the treatment of a variety
of different tumor types. Herein, we report a study
that determined the distribution, metabolism, and
excretion of selumetinib in healthy male volunteers.
Methods: In this open-label, single-center, Phase I
clinical trial, 6 subjects received a single 75-mg dose
of [14C]-selumetinib. Blood and excreta samples
were collected for pharmacokinetic and radiometric
analyses. Tolerability monitoring was performed
throughout the study.
Findings: The Cmax of plasma selumetinib was
1520 ng/mL at 1 hour postdose and declined with a t1/2
of 13.7 hours. Over a 216-hour postdose collection
period, total dose recovery was 93% of the radioactive
dose, with 59% recovered from feces and 33% from
urine. Circulating drug-related material was primarily
associated with plasma, with minimal distribution into
red blood cells. Selumetinib was the major circulating
drug-related component and accounted for 40% of the
plasma radioactivity (mean of AUC0–72h pool). The major
circulating metabolite (M2; accounting for 22% of the
plasma radioactivity) resulted from multiple biotransfor-
mation pathways, including loss of the ethanediol moiety
in combination with glucuronidation. A further 6 circu-
lating metabolites were identiﬁed, each accounting for
between 2% and 7% of plasma radioactivity. Selumetinib
was a minor component in urine, accounting forr1% of*Current afﬁliation: [Cyprotex, Macclesﬁeld, Cheshire, United
Kingdom]
†Current afﬁliation: [Sandoz Pharmaceuticals, Holzkirchen,
Germany].
November 2016the dose. M2 was the most abundant metabolite in urine,
accounting for 10% of the dose, and there were 5 other
metabolites accounting for between 1% and 10% of the
dose. In feces, selumetinib accounted for a mean of 19%
of the dose. Also present were 7 metabolites accounting
for between 1% and 9% of the dose. The majority of the
dose was recovered as metabolites, indicating that the liver
is the major route of drug elimination. There were no
tolerability concerns.
Implications: The ﬁndings from this study will
inform the label and will contribute to the under-
standing of the clinical pharmacology of selumetinib.
ClinicalTrials.gov identiﬁer: NCT01931761. (Clin
Ther. 2016;38:2447–2458) & 2016 The Authors.
Published by Elsevier HS Journals, Inc.
Key words: excretion, metabolism, pharmacoki-
netics, selumetinib.INTRODUCTION
Selumetinib (AZD6244, ARRY-142886; Figure 1) is a
marker extraction kernel 1/2 inhibitor1 with a short
t1/2.
2,3 It has shown activity in a variety of different
tumor types,4–6 and is currently being investigated in a
Phase III trial for differentiated thyroid cancer7 and in
a Phase II registration trial for neuroﬁbromatosis
type 15 (ClinicalTrials.gov identiﬁers: NCT01843062http://dx.doi.org/10.1016/j.clinthera.2016.09.002
0149-2918/$ - see front matter
& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Structures of selumetinib (A) and
N-desmethyl selumetinib (B).
Clinical Therapeuticsand NCT01362803, respectively). It is a regulatory
expectation and important to characterize the
absorption, distribution, metabolism, and excretion
of investigational drugs.8 Such information will
inform both the risks of giving the drug to renally
and hepatically impaired patients and the risk for
drug–drug interactions. An excretion balance study in
humans receiving radiolabeled drug is the usual way that
this is performed. Based on in vitro data, selumetinib is
believed to be mainly metabolized by cytochrome P450
(CYP) enzymes (ie, CYP3A4 and -2C19) and by the
uridine diphosphate glucuronosyltransferase (UGT) 1A1
(report no. [be000021-21], data on ﬁle, [AstraZeneca,
Cheshire, UK]); consequently, metabolism is expected to
play a key role in the clearance of selumetinib.
In pivotal studies, selumetinib is administered twice
daily at 75 mg under fasted conditions. Absorption is
relatively rapid, with the Tmax typically being 1.5
hours and t1/2 being 13 hours. An N-desmethyl
metabolite (Figure 1) that, is 3- to 5-fold more
potent than selumetinib based on in vitro cellular
ERK1/2 phosphorylation inhibition assays, has
been characterized in previous studies (study
NCT02093728 and NCT02046850, data on ﬁle,2448[AstraZeneca, Cheshire, UK]). This metabolite has
been shown to be produced in vitro by a number of
enzymes, including CYP2C19, -2C9, -2C8, and -1A2,
and typically circulates at concentrations of 7%
relative to selumetinib in patients.9
We report here the results from a Phase I study
that evaluated the routes and rates of excretion of [14C]-
radiolabeled selumetinib and N-desmethyl selumetinib
in plasma and the percentages of the radioactive dose
recovered from urine and feces in healthy male subjects.
The pharmacokinetic (PK) properties of selumetinib and
N-desmethyl selumetinib in plasma were determined,
and the metabolite proﬁles and distribution, elimination,
excretion in plasma and excreta samples were charac-
terized. In addition, the tolerability of a single dose of
[14C]-selumetinib was evaluated.SUBJECTS AND METHODS
This Phase I, open-label, single-center, single-dose study
was designed to examine the PK properties, distribu-
tion, metabolism, excretion, and tolerability of selume-
tinib in healthy male subjects (ClinicalTrials.gov
identiﬁer: NCT01931761). The study was performed
in accordance with the standards of the Declaration of
Helsinki and the International Conference on Harmo-
nisation/Good Clinical Practice, and was approved by
an institutional review board. Written informed consent
was obtained from all subjects prior to study entry.
Participants
The key inclusion criteria were as follows: male
subjects aged 50 to 65 years (inclusive), with regular
bowel movements and identiﬁed as healthy based
on their medical history and physical examination,
laboratory parameters, ECG, echocardiography, and
eye examination (all performed prior to dosing); a
body mass index of 18 to 32 kg/m2 (inclusive); a body
weight of 50 to 100 kg (inclusive); and a creatinine
clearance rate 450 mL/min, as calculated using the
Cockcroft-Gault formula.
Subjects were ineligible for inclusion based on the
following criteria: history or presence of central serous
retinopathy or retinal vein thrombosis; intraocular
pressure of421 mm Hg and/or uncontrolled glaucoma;
radiation exposure from clinical studies of 45 mSv in
the preceding 12 months or of 410 mSv in the
preceding 5 years; left ventricular ejection fraction of
o55%; history of any clinically important disease orVolume 38 Number 11
A.W. Dymond et al.disorder; history or presence of gastrointestinal, hepatic,
and/or renal disease and/or any other condition known
to interfere with the absorption, distribution, metabo-
lism, or excretion of drugs; current smokers or those
who have smoked or used nicotine products within the
previous 3 months; presence or history of alcohol abuse;
excessive intake of caffeine; use of any prescribed or
nonprescribed medication, particularly one with
enzyme-inducing properties, in the 4 weeks prior to
study drug administration; and/or any intake of grape-
fruit, grapefruit juice, Seville oranges, or related products
within 7 days prior to study admission.
Study Design
Six healthy male subjects received 3  25 mg
(free base equivalents; capsule formulation used
in ongoing Phase III studies) of [14C]-selumetinib
Hyd-Sulfate oral capsules, each containing 5.69
MBq, for a total radioactivity of 17.07 MBq (target
amount per capsule, 7.52 MBq) as a single dose on
day 1. Subjects were fasted from 10 hours prior to the
administration of selumetinib and remained fasted for
4 hours postdose. No ﬂuids were allowed from 1 hour
prior to selumetinib administration until 1 hour
postdose, except the water needed (240 mL) to
consume selumetinib; thereafter, subjects were
allowed free access to water. Subjects were to remain
at the study center for up to 7 days following receipt
of selumetinib, for the collection of blood, urine, and
fecal samples and for medical monitoring. The length
of the residential period could be reduced or extended
if deemed appropriate based on emerging data.
Sample Collection
Blood, plasma, urine, and fecal samples were
collected to determine drug concentrations and total
radioactivity. Samples were initially planned to be
collected up to 168 hours; however, as excretion was
protracted in 1 subject, the collection of excreta was
extended to at least 216 hours for all subjects. Plasma
and fecal samples were stored at –201C, and blood
and urine samples were stored at 41C until analysis.
Blood samples for analysis of plasma selumetinib
and N-desmethyl selumetinib, plasma radioactivity,
and blood radioactivity were taken at 0, 0.5, 1, 1.5, 2,
2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 144
hours. Due to the extended residence time, additional
samples (168, 192, 216, and 240 hours) were taken
to monitor the concentration of compound-relatedNovember 2016material while the subjects remained at the clinic.
Blood samples for metabolite proﬁling and identiﬁ-
cation were taken at 0, 2, 4, 12, 24, 48, and 72 hours.
Urine samples were taken at 0–6, 6–12, and 12–24
hours and then daily until a minimum of 216 hours
postdose. Fecal samples were taken at 0–12 and
12–24 hours and then daily until a minimum of
216 hours postdose. Urine and fecal samples beyond
216 hours postdose were taken to achieve higher
recovery of the dose if appropriate.
Bioanalysis
Plasma samples (K2EDTA anticoagulant) were kept
frozen at –201C or colder. Samples from the study
were analyzed for selumetinib and N-desmethyl selu-
metinib concentrations using an LC-MS/MS method,
with concentration ranges of 2 to 2000 ng/mL for
selumetinib and 2 to 500 ng/mL for N-desmethyl
selumetinib. Samples were spiked with 13C6 stable
label internal standards, and extracted by protein
precipitation using 4 volumes of methanol:acetoni-
trile. After centrifugation, the supernatants were
reduced to dryness under nitrogen at 501C and
reconstituted in methanol:water before analysis.
The extract was subjected to HPLC analysis using
a Luna C18 50  2 mm column (Phenomenex,
Torrance, California); the 5-mm particle size analytical
column was maintained at 301C. A gradient mobile
phase system was used with acetonitrile with a ﬂow
rate of 0.500 mL/min and the gradient running from
25% to 65% over 2 minutes, then increasing to 95%
over 0.1 minute and held for 0.5 minutes before
re-equilibration.
Quantiﬁcation was accomplished using either an
API 5000 or 5500 triple quadruple mass spectrometer
(AB Sciex, Foster City, California). Mass spectrometry
was run in positive electrospray, multiple-reaction
monitoring, with an ion spray voltage of 5500 V
and TurboIonSpray temperature of 6001C (AB Sciex).
The following transitions were monitored for the
analytes: selumetinib, 459.0/397.2; N-desmethyl selu-
metinib, 445.3/383.1. The accuracy and precision of the
analytical method were previously described.10
For selumetinib, the within-batch mean accuracy
ranged from 94.0% to 104.0%, and the within-batch
precision (%CV) ranged from 3.3% to 6.7%. The
between-batch mean accuracy ranged from 92.7% to
100.0%, and the between-batch precision ranged
from 3.3% to 7.0%.2449
Clinical TherapeuticsFor N-desmethyl selumetinib, the within-batch
mean accuracy ranged from 93.1% to 112%, and
the within-batch precision (%CV) ranged from 2.2%
to 5.0%. The between-batch mean accuracy ranged
from 98.3% to 103.5%, and the between-batch
precision ranged from 3.2% to 10.1%.
Radiometric Analysis
Duplicate samples of urine (1 g) and plasma
(0.1–0.5 mL) were taken for direct determination of
radioactivity. Fecal samples were weighed and homo-
genized with a volume of water sufﬁcient to produce a
paste, using a commercial blender. Radioactivity levels
in fecal homogenate and whole blood were deter-
mined after combustion in oxygen using an automatic
sample oxidizer (model 307; PerkinElmer, Waltham,
Massachusetts). The combustion products were
absorbed into CarboSorb (PerkinElmer) and mixed
with the scintillator cocktail PermaFluor Eþ
(PerkinElmer) for measurement of radioactivity. The
efﬁciency of the oxidizer was checked using carbon-14
standards (Spec-Check; PerkinElmer) and was494%.
Each batch of sample results was corrected for the
oxidizer efﬁciency.
Radioactivity levels in urine, plasma, and dose-
bottle rinses were quantiﬁed directly using liquid
scintillation counting with a liquid scintillation coun-
ter with automatic external standard quench correc-
tion. Urine and dose-bottle rinse samples were mixed
with Ultima Gold XR scintillant and counted on a
2300TR Tri-Carb Scintillation Counter (PerkinElmer).
Plasma samples were mixed with Ultima Gold scintil-
lant and counted on a 1414 Guardian Scintillation
Counter (PerkinElmer). Detected counts per minute
were converted to disintegrations per minute using
quench correction.
Metabolite Profiling and Identification
Sample Preparation
Time-normalized plasma samples (0–72 hours)
were prepared for each subject using the approach
described by Hamilton et al11 to produce samples
representative of the AUC. Each pool was treated with
acetonitrile (1:2 vol/vol) and centrifuged (2000g for
10 minutes at 41C) and the supernatant removed. To
recover additional drug-related material, the plasma
pellets were further washed using mixtures (5 mL)
of either acetonitrile/water (9:1 vol/vol or 4:1 vol/vol)
or methanol/water (4:1 vol/vol). The combined2450supernatants were reduced to dryness under a stream
of nitrogen (351C) and reconstituted in 10% acetoni-
trile:90% water (vol/vol) prior to analysis by HPLC
with MS detection and quantiﬁcation via fraction
collection and off-line 96-well microplate scintillation
analysis (HPLC-RAD-MSn).
Urine was pooled for each subject by combining
5% by weight of each time point sample. Samples
from individual time points were included if they
contained Z1% of the dosed radioactivity. The urine
pools were centrifuged (2000g for 10 minutes at 41C)
prior to analysis by HPLC-RAD-MSn.
Fecal homogenates were pooled for each subject by
combining 5% by weight of each time point sample.
Samples from an individual time point were included
if they contained Z1% of the dosed radioactivity.
Aliquots of the pooled fecal samples were treated
with acetonitrile (3:5 wt/vol), mixed, sonicated, and
centrifuged (2000g for 10 minutes at 41C) and the
supernatant removed. Additional extractions were
performed using the same approach but with mixtures
(5 mL) of acetonitrile and water (4:1 vol/vol and 1:1
vol/vol). The combined supernatants were reduced
to dryness under a stream of nitrogen (351C) and
reconstituted in 10% acetonitrile:90% water prior to
analysis by HPLC-RAD-MSn.
Chromatography and Mass Spectrometry
Plasma and fecal extracts and centrifuged urine
samples were injected onto a variable-gradient re-
verse-phase HPLC system, which utilized a CSH C18
column (2.5 mm, 150  4.6 mm; Waters, Milford,
Massachusetts), with 2 mobile phases consisting of
5% acetonitrile:95% water (vol/vol) plus 0.1% formic
acid (vol/vol) and acetonitrile plus 0.1% formic acid
(vol/vol), at a total ﬂow rate of 1 mL/min. The
postcolumn eluent was split (4:1), with the majority
of the ﬂow directed to a liquid handler for fractio-
nation into 96-well ScintiPlates (PerkinElmer); the
remainder of the ﬂow was directed to an LTQ
Orbitrap XL linear ion-trap mass spectrometer
(Thermo Fisher Scientiﬁc, Kalamazoo, Michigan),
which was equipped with an electrospray interface
operating in positive ion mode. Full scan data were
acquired over the mass range 100 to 1000 amu. MS2
and MS3 data for unchanged drug and metabolites
were acquired with normalized collision energies of 35
and 40 eV, respectively. Reconstructed radiochroma-
tograms were produced following import of 96-wellVolume 38 Number 11
A.W. Dymond et al.ScintiPlate count data into Laura software version
4.1.7.70 (LabLogic Systems, Brandon, Florida).
The count data were collected using a Microbeta
scintillation counter (PerkinElmer) following removal
of solvent from the plates. Data from the LTQ
Orbitrap XL mass spectrometer were acquired and
processed using Xcalibur software version 2.0.7
(Thermo Fisher Scientiﬁc).Pharmacokinetic Parameters
PK parameters were determined by noncompart-
mental analysis using Phoenix WinNonlin version 6.3
(Certara, Princeton, New Jersey). PK parameters were
derived by the following methods: Cmax and Tmax
were determined by inspection of the concentration–
time proﬁles; λz was calculated by log-linear regression
of the terminal portion of the plasma concentration-
time proﬁles; terminal half-life (t1/2λz) was calculated
as Ln(2)/λz; the AUC was calculated using the linear
up/log down trapezoidal rule up to measurable time
points and extrapolated to inﬁnity using λz; apparent
clearance was determined from the ratio of dose/AUC.
Apparent volume of distribution was determined from
the mean residence time  apparent clearance.n 
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Each subject underwent screening in the 28 days
prior to dosing to conﬁrm eligibility. Medical evalua-
tions were performed on day –1 (baseline), on the day
of dosing (predose), and at follow-up/discharge (on
day 7 or on the last day of urine/fecal collection,
whichever was later). Assessments included recording
of concurrent medications, a complete physical exami-
nation, 12-lead ECG, echocardiography, clinical
chemistry, hematology, urinalysis, supine blood pres-
sure and pulse rate, body weight, and recording of any
adverse events (AEs) and serious AEs. Vomit within
6 hours of dosing was analyzed for radioactivity.Time (h)
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Figure 2. Profile of plasma and blood
radioactivity and selumetinib and
N-desmethyl selumetinib in plasma
over time (semilogarithmic scale).Statistical Analysis
Given the exploratory nature of the study, no
formal statistical hypothesis testing was performed.
The statistical analysis was descriptive and consisted
of subject listings, graphs, and summary statistics
comprising geometric means, %CVs, arithmetic
means, SDs, medians, and minimal and maximal
values as appropriate.November 2016RESULTS
Subjects’ Demography and Baseline
Characteristics
Six white men were recruited and received
study treatment. Mean baseline demographic charac-
teristics were as follows: age, 56 years (range,
52–61 years); weight, 83.1 kg (range, 68.6–91.6 kg);
and body mass index, 27.2 kg/m2 (range, 23.7–
29.6 kg/m2).
Plasma Pharmacokinetics
Plasma concentration–time plots of selumetinib and
N-desmethyl selumetinib are presented in Figure 2,
and the key PK parameters are presented in Table I.
The geometric mean Cmax of selumetinib was 1520
ng/mL, and AUC, 4510 ng h/mL. Selumetinib was
rapidly absorbed, with a median Tmax of 1 hour
(range, 1–1.5 hours). Concentrations of selumetinib
declined over time, with a mean terminal t1/2 of
13.7 hours. Concentrations of the active metabolite
N-desmethyl selumetinib were 7% relative to
selumetinib.
Renal clearance was not formally calculated,
but the mean estimate of renal clearance (fraction of
dose excreted o1%  apparent clearance 15.7 L/h)
was o0.157 L/h, which is in agreement with ﬁndings
from a renal impairment clinical study (study no.
[NCT02063204], data on ﬁle, Dymond et al, [Astra-
Zeneca], [Cheshire, UK], [state]).2451
Table I. Summary of key pharmacokinetic parameters (N ¼ 6).
Parameter
Plasma
Selumetinib
Plasma N-desmethyl
Selumetinib
Whole Blood
Radioactivity
AUC, GM (%CV), ng h/mL 4510 (19.2) 351 (23.1) 8200 (26.8)
Cmax, GM (%CV), ng/mL 1520 (28.5) 109 (23.9) 1390 (17.6)
Tmax, median (range), h 1.00 (1.00–1.50) 1.00 (1.00–1.50) 1.00 (1.00–1.50)
t1/2, mean (SD), h 13.7 (5.04) 9.40 (1.01) 56.8 (48.0)
CL/F, mean (SD), L/h 15.7 (2.87) NR 8.78 (2.07)
V/F, mean (SD), L 146 (48.5) NR 359 (232)
CL/F ¼ apparent clearance; GM ¼ geometric mean; NR ¼ not reported; V/F ¼ apparent volume of distribution.
Clinical TherapeuticsPlasma and Blood Radioactivity
A full proﬁle of plasma samples was collected for
radiometric analysis; however, due to bioanalytical
challenges, the plasma PK radioactivity parameters
derived from the full proﬁle of plasma samples were
considered to be unreliable, and therefore a reduced
number of plasma samples collected for metabolite
proﬁling was used for radiometric analysis instead.
Using this reduced plasma sample set, a comparison
of the radioactivity concentration–time plot with
the plasma selumetinib concentration–time plot
demonstrated that total plasma radioactivity levels
were consistently higher and declined more slowly
(Figure 2). This ﬁnding is consistent with the presence
of circulating metabolites.
Whole-blood radioactivity concentrations were
lower than was plasma radioactivity at equivalentTable II. Concentration ratios (%) to total plasma radio
(%CV).
Ratio 2 h 4 h
Plasma selumetinib 54.2 (6.0) 50.0 (7.1)
Plasma N-desmethyl selumetinib 3.98 (14.3) 3.72 (11.7)
Whole blood 60.3 (6.6) 59.7 (6.6)
Distribution into RBCs* 5.94 (75.7) 3.60 (109.5
ND ¼ not determined; RBCs ¼ red blood cells.
*The distribution into RBCs was determined by [(Cwb – (1 –
blood, Cp is concentration in plasma, and Ht is hematocrit (Ht w
Day –1 and follow-up).
2452times, ranging from 60% to 70%, and did not appear
to change with time (Table II). It was estimated that
the association of the radioactivity with the red blood
cell component of blood was 6%. There was no
indication of a trend in the change in the distribution
with time.
Excretion Balance
Excretion of the dose in urine and feces over time is
presented in Figure 3. One subject was excluded from
the summaries of fecal and total excretion because he
did not produce fecal samples in the ﬁrst week after
dosing. The vast majority of the total radioactive dose
was recovered in urine by 96 hours and in feces by
144 hours, with near-complete recovery of the dose
(93%) within a 9-day collection period. Fecal excre-
tion (mean, 59%) was the predominant eliminationactivity (N ¼ 6). Data are given as geometric mean
12 h 24 h 48 h 72 h
37.7 (14.9) 24.1 (5.6) 15.1 (19.6) ND (ND)
3.54 (9.9) 3.11 (20.4) ND (ND) ND (ND)
69.7 (7.5) 61.0 (3.9) 61.5 (4.5) 60.4 (4.1)
) 17.9 (25.0) 5.59 (87.0) 6.18 (77.3) 6.74 (45.7)
Ht)*Cp)/Cwb]*100, where Cwb is concentration in whole
as the mean value of the laboratory Ht data obtained from
Volume 38 Number 11
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nation in urine (mean, 33%).
Metabolite Profiling and Identification
Examples of the representative pooled metabolite
proﬁles are presented in plasma, urine, and feces
in Figure 4. The proposed metabolic pathways of
selumetinib are shown in Figure 5.
Metabolites in Plasma
Selumetinib was the major circulating drug-related
component, accounting for 40% of the plasma radio-
activity (mean of data from all subjects, AUC0–72h
pool). The major circulating metabolite, an amide
glucuronide, accounted for 22% of the plasma
radioactivity (mean of data from all subjects) and
was postulated to result from loss of the ethanediol
moiety in combination with glucuronidation and an
additional loss of 2 mass units, possibly due to further
oxidation of the N-methylbenzimidazole moiety or
intramolecular cyclization (M2; m/z 571). A further
6 metabolites were identiﬁed, each accounting for
between 2% and 7% of the circulating drug-related
material (mean of data form all subjects), including
metabolites resulting from N-demethylation in
combination with the loss of the ethanediol moiety,
glucuronidation, and further oxidation of the
benzimidazole moiety or intramolecular cyclization
(M1; m/z 557); N-demethylation in combination withNovember 2016glucuronidation (M3; m/z 619); direct glucuronida-
tion of selumetinib (M4; m/z 633); N-demethylation
(M8; m/z 433); N-demethylation in combination
with oxidation of the primary alcohol group to a
carboxylic acid (M11; m/z 457); and a carboxylic acid
resulting from hydrolysis of the amide group (M15;
m/z 398). A number of trace drug-related components
(o2% of the circulating radioactivity) were identiﬁed,
including the primary amide resulting from loss of the
ethanediol moiety (M14; m/z 397) and components
involving N-demethylation, glucuronidation, loss of
the ethanediol moiety, mono-oxidation, and a loss of
2 mass units, possibly due to further oxidation of
the N-methylbenzimidazole moiety or intramolecular
cyclization.
Metabolites in Urine
Selumetinib was a minor drug-related component
in urine, accounting for r1% of the dose in all
subjects. The most abundant metabolite identiﬁed in
urine was M2 (m/z 571), which accounted for 10% of
the dose (mean of data from all subjects). Metabolites
accounting for between 1% and 10% of the dose in
the urine (mean of data from all subjects) included M1
(m/z 557), M3 (m/z 619), M4 and another direct
glucuronide conjugate of selumetinib, M7 (both,
m/z 633), and M8 (m/z 433). Trace drug-related
components included the primary amide (M14; m/z
397) and carboxylic acid (M15; m/z 398) metabolites.
Metabolites in Feces
Selumetinib accounted for between 6% and 34%
of the dose in the feces of individual subjects, with the
exception of the subject who provided limited fecal
samples up to 168 hours postdose, in whom un-
changed selumetinib accounted for o1% of the dose.
Mean percentages of selumetinib dose recovered in
feces were 23% and 19% when this subject’s data
were excluded and included, respectively. Seven me-
tabolites accounted for between 1% and 9% of the
dose in feces (mean of data from all subjects):
the primary amide metabolite (M14; m/z 397), the
N-desmethyl metabolite (M8; m/z 433), the carboxylic
acid metabolite (M15; m/z 398), and product resulting
from loss of the ethanediol moiety in combi-
nation with N-demethylation (M12; m/z 383), loss
of the ethanediol moiety in combination with
N-demethylation and mono-oxidation (M13; m/z 399),
loss of the ethanediol moiety in combination with2453
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Figure 4. Reconstructed radiochromatography of AUC in pooled human plasma (A), urine (B), and feces (C)
after a single 75-mg oral dose of [14C]-selumetinib in a representative subject.
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Figure 5. Proposed metabolic pathways of selumetinib. Square brackets indicate matrices in which metabolite
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*Plasma values indicate percentage chromatogram only. No value following matrix indicates
unquantifiable metabolite in the matrix. Bold type denotes 410% dose excreted as this metabolite
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A.W. Dymond et al.N-demethylation and ribose conjugation (M9; m/z
515), and loss of the ethanediol moiety in combination
with a loss of 2 mass units, possibly due to further
oxidation of the N-methylbenzimidazole moiety or
intramolecular cyclization (M10; m/z 395).
Tolerability
Two of the six subjects in the study reported Z1
AE: 1 subject reported lymph node pain and vomiting
(at 168–192 hours after dosing, and therefore was
considered unlikely to contain signiﬁcant amounts of
radioactivity), while the other subject reported upper
abdominal pain and spurious diarrhea. All of the AEsNovember 2016reported in the study were assessed by the Investigator
as being mild in intensity and not related to selume-
tinib. All AEs were resolved by the end of the study.DISCUSSION
This Phase I study examined the absorption, distribu-
tion, and metabolism of selumetinib by investigation
of the routes and rates of excretion of [14C]-radio-
labeled selumetinib and its metabolite, N-desmethyl
selumetinib in healthy male volunteers. Almost com-
plete recovery of the total radioactive dose (93%) was
from urine and feces within a 9-day collection period.2455
Clinical TherapeuticsModerate elimination in urine (33%) as metabolites of
selumetinib was detected (the most abundant metab-
olite, at 10% of the dose, was the amide glucuronide
[M2]), with o1% as unchanged selumetinib. The
fraction of dose recovered in feces was 59%, with
selumetinib accounting for a mean of 19% of the dose
and 7 metabolites each accounting for between
1% and 9% of the dose. Hence, the majority of
the radioactive dose was recovered as metabolites of
selumetinib, indicating that the liver plays a major role
in the elimination of selumetinib and its metabolites.
In this study, of the 19% of dose recovered as
unchanged selumetinib in feces, it was not possible to
differentiate the portion that was extracted from the
systemic circulation from the amount of unabsorbed
dose or that which had resulted from gut microbial
degradation of metabolites back to the parent drug.12
In a separate study, the absolute bioavailability
of a single oral dose of selumetinib 75 mg in
healthy subjects was 62% (90% CI, 60.1–64.1), as
determined by coadministration of an intravenous
80-μg microradiolabeled dose of [14C]-selumetinib
( study no. 2014-002993-35, data on ﬁle, EudraCT,
London, UK). The fraction absorbed was estimated to
be 71%, based on the intravenous clearance and
assuming normal hepatic blood ﬂow in a 70-kg
human to be 87 L/h based on the approach of
Gabrielsson and Weiner.13 Based on these data, it is
estimated that 10% of a 75-mg oral dose of
selumetinib was removed by ﬁrst-pass effects, which
suggests that this mechanism and the amount of
unabsorbed drug contribute equally to the amount
of unchanged selumetinib recovered in feces.
The plasma PK of selumetinib and N-desmethyl
selumetinib in this study were similar to those
reported in previous studies of single-dose selumetinib
Hyd-Sulfate 75-mg capsules PO in healthy subjects
(study nos. NCT02093728 and NCT02046850, data
on ﬁle, [AstraZeneca, Cheshire, UK]). Based on time-
matched concentration ratios, selumetinib accounted
for 54.2% of total plasma radioactivity at 2 hours,
reducing to 15.1% at 48 hours, while N-desmethyl
selumetinib accounted for 3.98% at 2 hours, reducing
to 3.11% at 24 hours; hence, total plasma radio-
activity concentrations appeared to show a slower
decline than plasma selumetinib and N-desmethyl
selumetinib concentrations, indicating the presence
of other circulating metabolites with greater systemic
retention than selumetinib. The concentration ratios2456of whole blood to plasma total radioactivity ranged
from 60% to 70% and did not show any time
dependency, showing plasma to be an appropriate
matrix for analysis of selumetinib.
Due to the lower systemic exposure of the
N-desmethyl metabolite in relation to selumetinib,
plasma concentrations were measurable only to
24 hours, whereas detectable concentrations of
selumetinib were achieved to 48 hours. The apparent
difference in the derived elimination half-life between
the parent and metabolite was likely due to the
different amounts of data used to deﬁne the elimi-
nation phase, and it is possible that the elimination
half-life of the metabolite could have been under-
estimated. The shapes of the curves of selumetinib
and N-desmethyl metabolite are similar.
Circulating drug-related material was primarily
associated with plasma, with minimal distribution
into red blood cells (mean distribution into red blood
cells over the 72-hour sampling period, 7.66%).
Selumetinib was the major circulating drug-related
component and accounted for 40% of the plasma
radioactivity (mean of the AUC0–72h pool). The major
circulating metabolite (M2; accounting for 22% of
plasma radioactivity) resulted from multiple biotrans-
formation pathways, including loss of the ethanediol
moiety in combination with glucuronidation.
A further 6 circulating metabolites were identiﬁed,
each accounting for between 2% and 7% of plasma
radioactivity. In vitro studies indicated that the phase I
metabolism of selumetinib was predominantly via
CYP3A4, with some contribution from CYP2C19
and -1A2. Investigations into the relative contribution
of CYP and UGT enzymes to the overall clearance of
selumetinib indicated that 56% of the observed
in vitro intrinsic clearance of selumetinib could be
attributed to CYP metabolism, and 29%, attributed
to direct glucuronidation by UGT enzymes (ie,
excluding pathways in which phase I oxidation occurs
before glucuronidation). The UGT isoforms involved
in turnover of selumetinib were found to be UGT1A1
and -1A3. Based on ﬁndings from in vitro experi-
ments, the active N-desmethyl metabolite was metab-
olized by conjugation (glucuronidation) and CYPs.
(report no. [D6244 KMX028], data on ﬁle, [AstraZe-
neca, Cheshire, UK]). The data from this clinical mass
balance study showed that metabolic clearance was an
important route of clearance of selumetinib. The
metabolites detected in this study were products ofVolume 38 Number 11
A.W. Dymond et al.oxidation or/and glucuronidation and so these ﬁnd-
ings are in agreement with the key metabolic routes
identiﬁed in the in vitro experiments.
The results from this study are based on data from
healthy subjects with normal renal and hepatic function.
The metabolism, excretion, and PK ﬁndings reported here
may differ in patients in whom disease and any associated
difference in hepatic or renal function could alter the
disposition of the drug (study nos. [NCT02063204 and
NCT02063230], data on ﬁle, Dymond et al, [AstraZe-
neca], [Cheshire, UK]). Also, this was a single-dose study,
whereas long-term dosing is expected in clinical practice.
Accepting the limitations of the study, we believe the
study provides good insight into the disposition of the
drug in patients in clinical practice.
Issues were encountered in some of the analyses of
radioactivity in plasma and whole blood. These issues
manifested as high variability in replicates and
unusual kinetic trends. Further analysis was per-
formed on speciﬁc whole-blood and plasma samples
(40% and 27%, respectively). It was observed that, in
some instances, the variance between the ﬁrst
3 aliquots was415%. It was also observed that there
was an increase in concentration in whole blood that
was not reﬂected in the plasma. An additional
2 aliquots of whole blood and plasma were analyzed
and counted on the liquid scintillation counter in a
10-minute protocol. A further aliquot of whole blood
was analyzed in order to conﬁrm the additional
results. The whole-blood results generated from
aliquots in 2 speciﬁc liquid scintillation counting
batches have been excluded, and a mean of all other
data has been calculated and reported. High varia-
bility between aliquot results subsequently reduced
from 40% to 14%, with all of the remaining high-
variability results being near the lower limit of
quantiﬁcation. The results of the plasma analysis
and further analysis were considered unreliable, and
therefore a lower number of plasma samples, initially
intended for metabolite proﬁling, were analyzed to
derive quantitative radioactivity data. Variability and
kinetic trends in this analysis appeared reliable. This
observation suggests that there were no issues with the
sample-collection procedures but that a technical
problem was associated with the original analysis.
For metabolite proﬁling, time-normalized plasma sam-
ples (0–72 hours) from each subject were prepared using
the approach described by Hamilton et al11 to produce a
composite of aliquots from samples collected at theNovember 2016various time points; this composite was representative of
the AUC in that period. This is an accepted method for
providing a representative relative abundance of the
metabolites formed in a set time period. However, the
pooled-sample technique will not allow for the character-
ization of any change in the metabolite proﬁle with time.
The current study was limited in that it was performed
in 6 subjects; this small sample size was chosen to restrict
the number of healthy subjects exposed to a radioactive
dose. This sample size is typically used in human mass
balance studies and is accepted by regulatory authorities
(www.ema.europa.eu/docs/en_GB/document...guideline/
2012/07/WC500129606.pdf EMA guidance: Guideline
on the investigation of drug interactions (CPMP/EWP/
560/95/Rev. 1 Corr. 2**). June 2012).CONCLUSIONS
In this PK study of selumetinib in healthy male
volunteers, 93% of the dose was recovered within
9 days, with 59% in feces and 33% in urine. Urinary
elimination of unchanged selumetinib was minimal
(o1%). There were circulating metabolites of selume-
tinib and minimal distribution of drug-related material
in red blood cells. Metabolism of selumetinib included
N-demethylation, direct glucuronidation of selumetinib,
and conjugation of phase I metabolites. Proﬁling of the
metabolites circulating in plasma and excreted in urine
and feces indicated that oxidative and glucuronidation
mechanisms are both important metabolic routes.
[14C]-selumetinib Hyd-Sulfate appeared to have been
well tolerated. The ﬁndings from this study will inform
the label and will contribute to the understanding of the
clinical pharmacology of selumetinib.ACKNOWLEDGMENTS
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